Pham et al. used an ELISA-based approach to quantify binding of p52, RelA, c-Rel, and RelB to a consensus NF-κB site in 19 DLBCL-derived cell lines (14 GCB- and 5 ABC-DLBCL) as well as in nine GCB- and five ABC-DLBCL patient samples. The gene discussed is REL; the disease is diffuse large B-cell lymphoma.